Literature DB >> 8267038

Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients.

R K Silver1, S N MacGregor, J S Sholl, J M Hobart, M G Neerhof, A Ragin.   

Abstract

OBJECTIVE: We compared the use of aspirin alone with combined therapy (prednisone plus aspirin) in antiphospholipid antibody-positive obstetric patients with prior adverse pregnancy outcome. STUDY
DESIGN: Thirty-nine patients meeting specific laboratory and clinical inclusion criteria were randomized to receive either combined therapy (prednisone plus low-dose aspirin, n = 17) or aspirin alone (n = 22). The daily aspirin dose was 81 mg; prednisone was begun at 20 mg/day and increased or decreased on the basis of observed changes in serial antibody levels. Perinatal outcomes were compared between groups. Evaluation of treatment-related maternal complications and serial antibody titers was also accomplished.
RESULTS: Thirty-four randomized subjects were evaluable (prednisone plus low-dose aspirin, n = 12 vs aspirin only, n = 22); no perinatal losses were observed in the study cohort. Preterm delivery was experienced by significantly more patients receiving prednisone plus low-dose aspirin than aspirin only (8/12 vs 3/22, respectively; p = 0.003), and prednisone exposure appeared to be an independent risk factor for preterm birth.
CONCLUSIONS: The use of prednisone therapy in conjunction with low-dose aspirin does not appear to improve outcome and may provoke obstetric complications in antiphospholipid antibody-positive patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8267038     DOI: 10.1016/0002-9378(93)90410-k

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  24 in total

Review 1.  Diagnosis and management of inherited and acquired thrombophilias.

Authors:  F A Spencer; R C Becker
Journal:  J Thromb Thrombolysis       Date:  1999-04       Impact factor: 2.300

2.  Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.

Authors:  Eva N Hamulyák; Luuk Jj Scheres; Mauritia C Marijnen; Mariëtte Goddijn; Saskia Middeldorp
Journal:  Cochrane Database Syst Rev       Date:  2020-05-02

3.  Management of antiphospholipid syndrome.

Authors:  Nicoletta Del Papa; Nikoleta Vaso
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-08       Impact factor: 5.346

4.  Antiphospholipid Syndrome during pregnancy: the state of the art.

Authors:  Fosca A F Di Prima; Oriana Valenti; Entela Hyseni; Elsa Giorgio; Marianna Faraci; Eliana Renda; Roberta De Domenico; Santo Monte
Journal:  J Prenat Med       Date:  2011-04

Review 5.  The role of antiphospholipid antibodies (aPls) in infertile women: the long-lasting experience.

Authors:  Zdenka Ulcova-Gallova
Journal:  Reprod Med Biol       Date:  2014-10-07

Review 6.  Anticoagulant therapy and pregnancy.

Authors:  Aiko Makino; Mayumi Sugiura-Ogasawara
Journal:  Reprod Med Biol       Date:  2008-02-01

Review 7.  Management of obstetric antiphospholipid syndrome.

Authors:  Guilherme Ribeiro Ramires de Jesus; Flavia Cunha dos Santos; Camila Souto Oliveira; Wallace Mendes-Silva; Nilson Ramires de Jesus; Roger Abramino Levy
Journal:  Curr Rheumatol Rep       Date:  2012-02       Impact factor: 4.592

Review 8.  Anticardiolipin antibodies and cardiovascular disease.

Authors:  K W Muir
Journal:  J R Soc Med       Date:  1995-08       Impact factor: 5.344

Review 9.  Preventing venous thromboembolism during pregnancy and postpartum: crossing the threshold.

Authors:  Leslie Skeith
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 10.  Duration of anticoagulation treatment for thrombosis in APS: is it ever safe to stop?

Authors:  Sinthiya Punnialingam; Munther A Khamashta
Journal:  Curr Rheumatol Rep       Date:  2013-04       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.